South Street Advisors LLC Sells 38,829 Shares of Novo Nordisk A/S $NVO

South Street Advisors LLC reduced its position in Novo Nordisk A/S (NYSE:NVO) by 61.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,537 shares of the company’s stock after selling 38,829 shares during the period. South Street Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,362,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NVO. Bank of Hawaii purchased a new position in Novo Nordisk A/S during the 3rd quarter valued at approximately $256,000. NorthRock Partners LLC raised its holdings in shares of Novo Nordisk A/S by 9.6% during the 3rd quarter. NorthRock Partners LLC now owns 5,337 shares of the company’s stock worth $296,000 after acquiring an additional 467 shares in the last quarter. Newbridge Financial Services Group Inc. raised its holdings in shares of Novo Nordisk A/S by 717.9% during the 3rd quarter. Newbridge Financial Services Group Inc. now owns 2,102 shares of the company’s stock worth $117,000 after acquiring an additional 1,845 shares in the last quarter. Quinn Opportunity Partners LLC bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at approximately $12,541,000. Finally, FORA Capital LLC boosted its position in shares of Novo Nordisk A/S by 609.6% during the 3rd quarter. FORA Capital LLC now owns 22,337 shares of the company’s stock valued at $1,239,000 after acquiring an additional 19,189 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $37.99 on Friday. The stock’s fifty day moving average is $50.14 and its 200 day moving average is $51.79. Novo Nordisk A/S has a fifty-two week low of $35.85 and a fifty-two week high of $82.57. The firm has a market capitalization of $169.61 billion, a PE ratio of 10.95 and a beta of 0.73. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The company had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Dividend Announcement

The company also recently declared a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s payout ratio is currently 23.63%.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on NVO. The Goldman Sachs Group restated a “neutral” rating and issued a $41.00 price target (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. CICC Research assumed coverage on shares of Novo Nordisk A/S in a research report on Friday, January 9th. They set an “outperform” rating and a $73.50 price objective for the company. Jefferies Financial Group raised shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. TD Cowen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price on the stock. in a report on Tuesday. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. Four analysts have rated the stock with a Buy rating and nineteen have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $49.93.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo’s deal with telehealth/retail player Hims & Hers could broaden channels for GLP‑1 distribution and shift competitive dynamics in the obesity market; Hims shares have surged on the tie-up. Hims shares set for best week on record after new Novo Nordisk deal
• Positive Sentiment: Novo’s partnership with the WHO Foundation to support cardio‑renal‑metabolic programs expands its public‑health footprint and may support long‑term access and reputation in emerging markets. Novo Nordisk WHO Partnership Links Global Health Push With Valuation Story
• Neutral Sentiment: Zacks moved NVO from “strong sell” to “hold,” which slightly reduces near‑term sell‑side pressure but is not a bullish upgrade. Zacks.com
• Neutral Sentiment: Broader health‑care weakness today (NYSE Health Care Index decline) is adding to headline pressure across large pharma names, including NVO. Sector Update: Health Care Stocks Retreat Late Afternoon
• Negative Sentiment: The FDA issued a warning to Novo Nordisk about unreported semaglutide adverse events — the clearest near‑term catalyst for the share decline as it raises risks of inspections, disclosures, labeling changes, prescribing impacts and regulatory enforcement. FDA issues warning to Novo Nordisk on unreported semaglutide safety events
• Negative Sentiment: An investor class‑action/investigation notice (Pomerantz) has been announced, increasing legal risk and potential future claims tied to the disclosure of safety events. Pomerantz investor alert
• Negative Sentiment: Analyst downgrades and negative press—plus reporting that Novo Holdings’ assets shrank after the stock slump—are reinforcing selling momentum and investor concern about valuation and control‑group exposure. Novo Nordisk stock slump hits value of controlling shareholder

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.